We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Read MoreHide Full Article
Key Takeaways
Precigen's Papzimeos generated $74.6 million in revenues in the first six months of 2026.
Papzimeos sales more than doubled sequentially in Q2, while demand continued to grow into Q3.
Precigen is seeking European approval, while Papzimeos has FDA exclusivity through Aug. 14, 2032.
Precigen (PGEN - Free Report) is making steady progress on the back of strong commercial performance from its sole marketed drug Papzimeos (zopapogene imadenovec-drba). The product remains a key top-line driver for the company.
Papzimeos is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The drug provides Precigen with a differentiated commercial position and a potentially durable revenue base.
The therapy has demonstrated strong early commercial momentum since its approval and launch in 2025. In the first six months of 2026, the product generated $74.6 million in revenues. Importantly, product revenues from Papzimeos sales more than doubled sequentially during the second quarter of 2026.
Management noted that Papzimeos demand was continuing to grow as the third quarter progressed. The sustained commercial momentum could support further revenue growth for Precigen through the remainder of 2026.
Sales are expected to grow steadily as Precigen expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Papzimeos.
PGEN Thrives on Papzimeos Commercial Uptake
Precigen is pursuing additional growth opportunities outside the United States.
Precigen’s marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review. Approval in Europe could further boost revenue growth.
Meanwhile, Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals (INO - Free Report) is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application for INO-3107 is currently under review in the United States, with a decision from the FDA expected on Oct 30, 2026. INO remains focused on advancing the INO-3107 program toward a potential 2026 approval and commercialization.
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in HPV-driven cancers.
A multicenter phase II study is evaluating PRGN-2009 in combination with Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), in patients with recurrent or metastatic cervical cancer.
Merck’s biggest revenue driver, Keytruda, is approved for several types of cancers globally.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
PGEN’s Price Performance, Valuation and Estimates
Year to date, shares of Precigen have rallied 62.7% compared with the industry’s rise of 8.3%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Precigen is trading at a premium to the industry. Going by the price/book ratio, the stock currently trades at 55.63 times trailing 12-month book value, higher than 3.91 times for the industry. The stock is also trading above its five-year mean of 4.29.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 bottom line has improved from a loss of 2 cents per share to earnings of 25 cents over the past 60 days. During the same time, earnings estimates for 2027 have increased from 25 cents per share to 86 cents during the same time.
View the Zacks #1 Rank List
Image: Bigstock
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
Key Takeaways
Precigen (PGEN - Free Report) is making steady progress on the back of strong commercial performance from its sole marketed drug Papzimeos (zopapogene imadenovec-drba). The product remains a key top-line driver for the company.
Papzimeos is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The drug provides Precigen with a differentiated commercial position and a potentially durable revenue base.
The therapy has demonstrated strong early commercial momentum since its approval and launch in 2025. In the first six months of 2026, the product generated $74.6 million in revenues. Importantly, product revenues from Papzimeos sales more than doubled sequentially during the second quarter of 2026.
Management noted that Papzimeos demand was continuing to grow as the third quarter progressed. The sustained commercial momentum could support further revenue growth for Precigen through the remainder of 2026.
Sales are expected to grow steadily as Precigen expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Papzimeos.
PGEN Thrives on Papzimeos Commercial Uptake
Precigen is pursuing additional growth opportunities outside the United States.
Precigen’s marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review. Approval in Europe could further boost revenue growth.
Meanwhile, Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals (INO - Free Report) is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application for INO-3107 is currently under review in the United States, with a decision from the FDA expected on Oct 30, 2026. INO remains focused on advancing the INO-3107 program toward a potential 2026 approval and commercialization.
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in HPV-driven cancers.
A multicenter phase II study is evaluating PRGN-2009 in combination with Merck’s (MRK - Free Report) blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), in patients with recurrent or metastatic cervical cancer.
Merck’s biggest revenue driver, Keytruda, is approved for several types of cancers globally.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
PGEN’s Price Performance, Valuation and Estimates
Year to date, shares of Precigen have rallied 62.7% compared with the industry’s rise of 8.3%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Precigen is trading at a premium to the industry. Going by the price/book ratio, the stock currently trades at 55.63 times trailing 12-month book value, higher than 3.91 times for the industry. The stock is also trading above its five-year mean of 4.29.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 bottom line has improved from a loss of 2 cents per share to earnings of 25 cents over the past 60 days. During the same time, earnings estimates for 2027 have increased from 25 cents per share to 86 cents during the same time.
Image Source: Zacks Investment Research
PGEN’s Zacks Rank
Precigen currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.